MiMedx comments on CY26 Medicare PFS final rule

MiMedx (MDXG) Group commented on the Centers for Medicare and Medicaid Services, CMS, release of the CY 2026 Physician Fee Schedule, PFS, final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for skin substitutes. CMS is now acting, in the form of the new PFS, as well as other initiatives, to reduce the rampant fraud, waste and abuse that has plagued this industry. We believe these steps will help restore far more rational behavior, bringing stability and predictability to the market,” stated Joseph Capper, MIMEDX Chief Executive Officer. “There are details and mechanics we need to sort through, and we would have preferred to see our recommendations included in the final rule. However, this reform represents a major step in the right direction, and we will continue to advocate for further improvements over time. Our highest priority as we work through the transition is to ensure patients have continued access to our proven technology.”